Promoting “Low T”
- 12 August 2013
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 173 (15), 1458-1460
- https://doi.org/10.1001/jamainternmed.2013.6892
Abstract
Despite progress in raising the level of transparency about funding, conflicts of interest, and ghostwriting, drug companies remain free to pursue subtle and, therefore, effective means of marketing. Continuing medical education programs and “consensus” panels continue to be funded by companies selling products directly tied to the messages being conveyed by the resulting “educational” materials. And patient education materials continue to be created that, while factually accurate, subtly shift attitudes by including only selected facts and/or omitting ideas that would undermine the funder’s preferred paradigm.Keywords
This publication has 4 references indexed in Scilit:
- Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysisBMJ, 2013
- Accessibility and transparency of editor conflicts of interest policy instruments in medical journalsJournal of Medical Ethics, 2012
- The Natural History of Symptomatic Androgen Deficiency in Men: Onset, Progression, and Spontaneous RemissionJournal of the American Geriatrics Society, 2008
- “This may sting a bit”: cutting cme’s ties to pharmaThe AMA Journal of Ethic, 2006